Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MALT1 inhibitor ABBV-525

An orally bioavailable inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), with potential immunomodulating and antineoplastic activities. Upon oral administration, MALT1 inhibitor ABBV-525 targets, binds to, and inhibits the activity of MALT1. This inhibits MALT1-dependent CARD11-BCL10-MALT1 (CBM) signaling, thereby inhibiting the immunosuppressive function of regulatory T cells (Tregs) and upregulating the production of interferon-gamma (IFN-g) by Tregs in the tumor microenvironment (TME). This results in the inhibition of Janus kinase/signal transducers and activators of transcription (JAK/STAT) and nuclear factor-kappa B (NF-kB) signaling, induces apoptosis, and inhibits tumor cell growth. MALT1 belongs to the caspase family of proteases and is the active component of the CBM signaling complex. It plays an essential role in mediating the immunosuppressive activities of Tregs, and is overactivated in certain tumor cells, including non-Hodgkin B-cell lymphomas.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:ABBV 525
ABBV-525
ABBV525
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search